Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

SLU-PP-332 (5mg Vial) Dosage Chart - Peptide Dosages

SLU-PP-332 (5mg Vial) Dosage Protocol Experimental ERR-agonist "exercise mimetic" (small molecule) — preclinical (mouse) only; not approved. Mix & measure SLU-PP-332 · 5 mg Pre-filled with this protocol’s recommended BAC water and documented starting dose — ed

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SLU-PP-332 (5mg Vial) Dosage Protocol

Experimental ERR-agonist "exercise mimetic" (small molecule) — preclinical (mouse) only; not approved.

Mix & measure SLU-PP-332 · 5 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Murine-Equivalent Schedule (3 mL = ~1.67 mg/mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 5 mg vial → final concentration ~1.67 mg/mL (1,667 mcg/mL).

Murine daily dose: 1,250–2,500 mcg/day (murine-equivalent for a ~25 g mouse), given as two divided doses. This is not a human dose.

Easy measuring: At ~1.67 mg/mL, 1 unit ≈ 16.67 mcg on a U-100 syringe (units = mcg ÷ 16.67). The large 3.0 mL dilution keeps every dose at 37.5 units or more for accurate measuring.

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Retinalamin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Retinalamin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05IGF-1 DES — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. IGF-1 DES is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

The Mechanism That Frames Every Research Question

Every legitimate research question about Sermorelin ultimately traces back to its mechanism, so it is worth laying that out precisely. Sermorelin binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed predominantly on the somatotroph cells of the anterior pituitary. Receptor engagement activates the stimulatory Gs protein, which stimulates adenylyl cyclase, raising intracellular cyclic AMP. The rise in cAMP activates protein kinase A, which both promotes the immediate release of stored growth hormone and, through downstream transcription factors such as CREB and the pituitary-specific factor Pit-1, drives transcription of the GH gene and supports somatotroph proliferation.6 In short, Sermorelin does not supply growth hormone; it instructs the pituitary to make and release its own. The mechanics of that pituitary-level signaling are explored further in the site’s discussion of how Sermorelin affects pituitary signaling in endocrine research. Two features of this mechanism generate most of the compound’s theoretical appeal, and both deserve careful, non-inflated treatment. The first is preservation of feedback. Growth-hormone secretion is restrained by somatostatin, the hypothalamic “off” signal, and by IGF-1-mediated negative feedback. Because Sermorelin acts upstream at the pituitary rather than flooding the body with exogenous hormone, its output remains subject to these brakes. The practical implication, argued in the clinical literature, is that it is difficult to drive endogenous GH to grossly supraphysiological levels with a GHRH stimulus alone, because somatostatin tone rises to oppose it.4 This is a genuine and attractive property in principle — it is the mechanistic basis for the claim that GHRH-based approaches are “self-limiting” in a way that injected recombinant GH is not. The second is pulsatility. Physiological GH secretion is episodic, occurring in discrete pulses (especially during slow-wave sleep) against a low baseline. This pulsatile pattern is not incidental; the biological effects of GH depend partly on the pattern of exposure, not merely the total amount. A GHRH stimulus, working through the intact pituitary, tends to produce release that is more episodic than the flat, non-physiological profile of a recombinant GH injection.4 Restoring a more natural secretory rhythm, rather than simply raising the average, is one of the more scientifically interesting propositions attached to the compound. Here honesty requires a firm caveat. These are compelling mechanistic rationales, and they are frequently presented as though they were demonstrated clinical outcomes. They are not the same thing. That a GHRH analog preserves feedback and encourages pulsatility is a reasonable pharmacological expectation; that this translates into meaningful, durable benefit for body composition, sleep, recovery, or aging in otherwise-healthy adults is a separate empirical question that Sermorelin’s own evidence base does not robustly answer. The mechanism is the source of the hypotheses, not the confirmation of them. And the short half-life re-enters here: a molecule cleared within roughly ten to twelve minutes must be dosed to catch the physiological windows in which it can actually shape a pulse, which is why the timing conventions around it exist and why sustained effects cannot be assumed from a transient signal.3

Source: dosagepeptide.com ↗

Safety and Tolerability in the Research Setting

Safety and efficacy are separate questions, and it is entirely possible for a compound to be well tolerated while remaining unproven for the condition of interest. That is the current situation for NAD+ precursors in Parkinson’s disease. The short-term tolerability data, particularly for oral nicotinamide riboside, are reassuring within the limits of the trials conducted, but they are not a statement about long-term safety, about frail or elderly populations over years, or about drug interactions in people taking multiple Parkinson’s medications. The most directly relevant safety dataset is NR-SAFE, which was explicitly designed to probe tolerability at a high dose. Over four weeks, 3,000 mg of NR daily produced only mild adverse events, with no moderate or severe events and no significant excess over placebo; the most frequently reported events in the NR arm included extrapyramidal symptoms, headache, tremor, muscle cramps, fatigue, nausea, and dyspepsia, several of which overlap with the underlying disease and its treatment.2 The absence of painful flushing is notable because flushing is a classic dose-limiting effect of nicotinic acid (niacin); NR and nicotinamide generally avoid the flushing that niacin causes, which is one reason they are favored for chronic dosing. The lower-dose NADPARK trial similarly reported that 1,000 mg daily was well tolerated over 30 days.1 Broader supplement-safety literature on NR in non-Parkinson populations has generally supported tolerability at commonly studied doses, and NMN has likewise been reported to raise blood NAD+ safely in short studies of healthy adults.13 These reassurances come with substantial caveats that a careful reader should hold in mind. First, the trials are small and short. Twenty participants over four weeks, or thirty over one month, cannot detect uncommon adverse events or effects that only emerge with months to years of exposure, which is exactly the exposure that disease modification would require. Second, the populations were selected: early-stage, often newly diagnosed patients able to participate in a trial, not the full spectrum of advanced disease, multimorbidity, and polypharmacy seen in practice. Third, theoretical concerns exist that have not been resolved in humans. Because NAD+ metabolism intersects with cell proliferation and with the kynurenine pathway, and because some preclinical work has raised tissue-specific concerns about chronic high-dose precursor exposure (for example, questions about metabolite accumulation with sustained oral NMN in animal models), long-term safety cannot be assumed from short-term tolerability.13 Fourth, methylation load is a plausible consideration: clearance of excess nicotinamide consumes methyl groups, and the metabolic consequences of chronically high precursor intake over years are not well characterized in this population. There is also the matter of source and quality. In a research context, the identity, purity, and endotoxin status of a compound materially affect both the validity of an experiment and the safety of any handling. Injectable NAD+ preparations used outside regulated trials vary widely in provenance, and intravenous NAD+ administration in particular has been associated with infusion-related discomfort (nausea, chest tightness, flushing) that is typically managed by slowing the infusion rate but underscores that route and formulation matter.4 None of this constitutes clinical guidance. The appropriate summary is that oral NR appears well tolerated in the short term at the doses tested in early Parkinson’s trials, that other precursors and routes have thinner safety records, and that long-term safety in Parkinson’s disease specifically remains unestablished pending completed, published, adequately long trials.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step Frequency: one subcutaneous injection each day. The 4 mg/day dose and the 1–4–8 mg dose-ranging arms are real Phase 2 parameters[3][4], but Phase 2 results are early-stage and proven efficacy should not be assumed.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →